The CGPA and its Biosimilars Canada division welcome the Ontario government’s announcement of a $146 million investment in the next phase of its Life Sciences Strategy to help position the province as a global leader in life sciences.

The CGPA and its Biosimilars Canada division welcome the Ontario government’s announcement of a $146 million investment in the next phase of its Life Sciences Strategy to help position the province as a global leader in life sciences.

The CGPA and its Biosimilars Canada division welcome the Ontario government’s announcement of a $146 million investment in the next phase of its Life Sciences Strategy to help position the province as a global leader in life sciences.

The CGPA and its Biosimilars Canada division welcome the Ontario government’s announcement of a $146 million investment in the next phase of its Life Sciences Strategy to help position the province as a global leader in life sciences.

The CGPA and its Biosimilars Canada division welcome the Ontario government’s announcement of a $146 million investment in the next phase of its Life Sciences Strategy to help position the province as a global leader in life sciences.